3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
53
Sarcoma
5
Lymphoid
4
Myeloid
2
Gastrointestinal
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Prostatic Neoplasms
683
Carcinoma, Renal Cell
225
Urinary Bladder Neoplasms
195
Carcinoma, Transitional Cell
111
Breast Neoplasms
96
Kidney Neoplasms
89
Carcinoma, Non-Small-Cell Lung
82
Neoplasms
81
Melanoma
78
Ovarian Neoplasms
77
Colorectal Neoplasms
68
Neoplasm Metastasis
66
Non-Muscle Invasive Bladder Neoplasms
56
Lung Neoplasms
53
Pancreatic Neoplasms
46
Sarcoma
45
Stomach Neoplasms
42
Endometrial Neoplasms
41
Uterine Cervical Neoplasms
39
Wilms Tumor
33
Adenocarcinoma
33
Esophageal Neoplasms
31
Carcinoma, Hepatocellular
31
Squamous Cell Carcinoma of Head and Neck
30
Triple Negative Breast Neoplasms
29
Head and Neck Neoplasms
27
Testicular Neoplasms
24
Metastatic Castration-resistant Prostate Cancer
24
Neuroblastoma
23
Colonic Neoplasms
23
Interventions
trastuzumab deruxtecan
1
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Astrocytoma
×
Genitourinary
×
90 days
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled